We recognise our responsibility to minimise environmental impact, support our people and communities, and act as a trusted, long-term partner to our clients.
Focusing on measurable action, continuous improvement and transparency, our sustainability strategy ensures we deliver high quality sterile injectables while contributing positively to a more sustainable future for the pharmaceutical industry.
We are committed to embedding sustainable practices across our operations, facilities and supply chain. Taking a structured, evidence-based approach to sustainability we align our environmental ambitions with internationally recognised frameworks and standards.
This commitment reflects our belief that responsible manufacturing strengthens resilience, drives operational efficiency and supports the success of our clients.
In 2022, Symbiosis undertook a baseline carbon footprint assessment to better understand the emissions associated with sterile manufacturing operations and identify opportunities for meaningful action.
Reducing our environmental footprint is a key priority and the insights gained informed targeted investments and operational improvements to enhance energy efficiency and reduce emissions intensity, particularly during the design of our Bruce Building facility.
Symbiosis has committed to the Science Based Targets initiative (SBTi), ensuring our climate action is aligned with the latest climate science. We have committed to a science-based 1.5°C target by 2030, supporting global efforts to limit temperature rise and accelerate corporate decarbonisation.
Our near-term science-based emissions target has been approved by the SBTi and this validation provides assurance that our emissions reduction pathway is robust, credible and aligned with best practice.
At the Bruce Building, we have implemented several initiatives to improve energy efficiency and reduce reliance on fossil fuels:
These measures are estimated to reduce the energy required to manufacture each vial of biopharmaceutical drug product by ~25%, while also supporting long-term reductions in operational emissions.
Beyond energy and emissions, Symbiosis is committed to responsible business practices across all areas of operation. We maintain high standards of governance and work collaboratively with suppliers and partners to promote ethical and sustainable practices.
Our sustainability approach ensures that environmental responsibility is embedded alongside compliance, safety and product integrity, in line with our Quality and Regulatory standards.
Our approach to sustainability has been independently recognised by EcoVadis, the globally trusted provider of business sustainability ratings.
This badge reflects our ongoing commitment to implementing environmental, social and governance (ESG) principles across our operations.
Symbiosis is committed to continuous improvement initiatives to reduce our environmental impact. We will continue to invest in our facilities, monitor performance against targets and seek opportunities to further reduce our impact while supporting the needs of our clients.
Through science-based targets, responsible operations and transparent reporting, Symbiosis is committed to playing its part in building a more sustainable pharmaceutical supply chain.